There are currently 299 active clinical trials seeking participants for Cancer research studies. The states with the highest number of trials for Autism participants are California, Texas, New York and Florida.
Rare Tumors and Cancer Predisposition in Individuals and Families
NCT05350761
Recruiting
Background: Some people may be prone to develop cancer for many reasons. Factors that affect their risk include the genes they inherit and the environment they live and work in. Researchers want to learn more about the natural history of cancer. Objective: To understand how genes and environmental factors can cause tumors and related conditions. Eligibility: People of any age who: Have tumors of an unusual type, pattern, or number Have a family member with a history of cancer Have been e... Read More
Gender:
All
Ages:
All
Trial Updated:
04/11/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland +1 locations
Conditions: Cancer, Hereditary Neoplasms, Genetic Predisposition to Cancer, Environment
Register for Updates
Health Benefits of Writing Therapy Among Asian American Cancer Survivors
NCT06367959
Recruiting
To learn more about participant experience as a Chinese immigrant breast cancer survivor and how writing about participant experiences may affect participant's health.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Cancer
Register for Updates
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
NCT05346796
Recruiting
To understand the effectiveness and implementation of the SCP-PHR, we will conduct a hybrid type 1 effectiveness-implementation trial consisting of the following components: (A) a randomized clinical effectiveness trial, and (B) a mixed methods implementation study.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
04/10/2024
Locations: Indiana University School of Medicine, Indianapolis, Indiana
Conditions: Cancer
Register for Updates
Pan Tumor Rollover Study
NCT03899155
Recruiting
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: University of Arizona College of Medicine, Tucson, Arizona +343 locations
Conditions: Cancer
Register for Updates
Development and Validation of Harbinger Health Test for Early Cancer Detection
NCT05435066
Recruiting
This is a prospective, multi-center, observational study with a collection of biospecimens and clinical data from approximately 10,000 participants from up to 125 clinical network sites and locations in the United States. The objective of this study is to collect blood samples, tissue samples, and associated clinical data from participants with a variety of solid tumor and hematologic cancers and non-cancer participants for testing and the development of a screening test for early cancer detecti... Read More
Gender:
All
Ages:
Between 20 years and 79 years
Trial Updated:
04/09/2024
Locations: Southern Cancer Center, Daphne, Alabama +124 locations
Conditions: Cancer
Register for Updates
Strata PATH™ (Precision Indications for Approved Therapies)
NCT05097599
Recruiting
StrataPATH™ is a non-randomized, open-label trial designed to explore efficacy and safety of multiple FDA-approved and commercially available cancer therapies in new, biomarker-guided patient populations.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Genesis Cancer and Blood Institute, Hot Springs, Arkansas +14 locations
Conditions: Cancer, Advanced Solid Tumor
Register for Updates
Patient Derived Preclinical Models
NCT05324553
Recruiting
Study goal is to collect tumor specimens that may inform cancer biology to eventually improve outcomes for patients with cancer. This proposal represents a highly collaborative effort to support cancer research with the goal of developing novel therapeutic strategies using patient derived preclinical models. This study is being done to collect samples of tumor tissues, matched normal tissue when possible, and approximately 50 mL of blood.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Cancer
Register for Updates
A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
NCT06051695
Recruiting
The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express MSLN and have lost HLA-A*02 expression. The main questions this study aims to answer are: Phase 1: What is the recommended dose of A2B694 that is safe for patients Phase 2: Does the recommended dos... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/07/2024
Locations: UCSD Moores Cancer Center, La Jolla, California +8 locations
Conditions: Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer, Pancreas Cancer, Pancreatic Neoplasm, Colorectal Adenocarcinoma, CRC, Colon Cancer, Rectal Cancer, Cancer, Ovarian Cancer, Ovarian Neoplasms, Mesothelioma, Mesothelioma, Malignant, Ovary Cancer, Lung Cancer, MESOM
Register for Updates
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
NCT04981119
Recruiting
Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Design: This is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/07/2024
Locations: Banner Health, Gilbert, Arizona +12 locations
Conditions: Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, CRC, NSCLC, Pancreas Cancer, Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Mesothelioma, Malignant, Mesothelioma; Lung, Cancer
Register for Updates
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
NCT05736731
Recruiting
The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other solid tumors that express CEA and have lost HLA-A*02 expression. The main questions this study aims to answer are: Phase 1: What is the maximum or recommended dose of A2B530 that is safe for patients Phase 2: Does the recommended dose of A2B530 kill the solid tumor cel... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/07/2024
Locations: Banner Health, Gilbert, Arizona +9 locations
Conditions: Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent, Non-Small Cell Squamous Lung Cancer, NSCLC, NSCLC, Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, CRC, Colorectal Cancer Metastatic, Cancer
Register for Updates
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
NCT05405413
Recruiting
This is a single-arm Phase II study to measure the impact of Molecular Tumor Board treatment recommendations on treatment decision-making in clinical practice at the Dartmouth Cancer Center. Following tumor genetic profiling, subjects will be screened for eligibility. Eligible subjects' cases will be evaluated by the Dartmouth Cancer Center Molecular Tumor Board, and treatment recommendations will be entered into the medical record as per standard procedure. The primary endpoint is a survey res... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/06/2024
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Cancer
Register for Updates
mHealth for Young Adult Cancer Survivors
NCT05905250
Recruiting
We aim to refine and pilot test an 8-week phone- and app-based intervention to promote hope, and thereby mitigate life disruption caused by cancer diagnosis and treatment, among young adults (YAs); our proposal involves (Aim 1) formative research among YA survivors and healthcare providers; and (Aim 2) an randomized controlled trial (RCT) of the intervention vs. attention control among 150 YA cancer survivors. The proposed research is innovative in its use of: 1) a novel intervention target - ho... Read More
Gender:
All
Ages:
Between 20 years and 39 years
Trial Updated:
04/06/2024
Locations: George Washington University, Washington, District of Columbia
Conditions: Survivorship, Cancer, Psychological Well-Being
Register for Updates